tag :: antibodies Monoclonal

bookmarks (hide)
display
all
bookmarks only
bookmarks per page
5
10
20
50
100
sort by
added at
title
RSS
BibTeX
XML

No matching posts.

⟨⟨
⟨
⟩
⟩⟩

publications (hide)35
display
all
publications only
publications per page
5
10
20
50
100
sort by
added at
title
author
publication date
entry type
help for advanced sorting...
RSS
BibTeX
RDF
more...

1The Immunotherapy in Cancer Treatment Occurring Advancement in Using the Immune System to Combat Cancer
M. Vaidya. INTERNATIONAL JOURNAL OF TREND IN SCIENTIFIC RESEARCH AND DEVELOPMENT, 8 (1): 228-234 (February 2024)
8 months ago by @ijtsrd
show all tags
(ADCs),
(mAbs),
Antibodies
Antibody
CAR-T
Cancer
Conjugate
Cytokines
Drug
Immune
Monoclonal
Targeted-therapies,
cell
checkpoint,
immunapy,
therapy,
(ADCs),(mAbs),AntibodiesAntibodyCAR-TCancerConjugateCytokinesDrugImmuneMonoclonalTargeted-therapies,cellcheckpoint,immunapy,therapy,
(0)
copydeleteadd this publication to your clipboard
1Is it time for medicine-based evidence?
J. Concato. JAMA : the journal of the American Medical Association, 307 (15): 1641-3 (April 2012)6589<m:linebreak></m:linebreak>CER.
2 years ago by @jepcastel
show all tags
Abdominal
Abdominal:mortality
Abdominal:surgery
AirAmbulances
AirAmbulances:statistics&numericaldata
Ambulances
Ambulances:statistics&numericaldata
AngiogenesisInhibitors
AngiogenesisInhibitors:therapeuticuse
Antibodies
AntineoplasticCombinedChemotherapyProtocols
AntineoplasticCombinedChemotherapyProtocols:th
AorticAneurysm
Carcinoma
EmergencyMedicalServices
EmergencyMedicalServices:methods
EndovascularProcedures
EndovascularProcedures:mortality
Female
Humanized
Humanized:administration&dosage
Humans
Intensity-Modulated
Intensity-Modulated:adverseeffects
KidneyNeoplasms
KidneyNeoplasms:mortality
KidneyNeoplasms:surgery
LungNeoplasms
LungNeoplasms:drugtherapy
Male
Medicare
Medicare:statistics&numericaldata
Monoclonal
Nephrectomy
Nephrectomy:methods
Nephrectomy:mortality
Non-Small-CellLung
Non-Small-CellLung:drugtherapy
ProstaticNeoplasms
ProstaticNeoplasms:radiotherapy
RadiationInjuries
Radiotherapy
VascularSurgicalProcedures
VascularSurgicalProcedures:mortality
WoundsandInjuries
WoundsandInjuries:mortality
AbdominalAbdominal:mortalityAbdominal:surgeryAirAmbulancesAirAmbulances:statistics&numericaldataAmbulancesAmbulances:statistics&numericaldataAngiogenesisInhibitorsAngiogenesisInhibitors:therapeuticuseAntibodiesAntineoplasticCombinedChemotherapyProtocolsAntineoplasticCombinedChemotherapyProtocols:thAorticAneurysmCarcinomaEmergencyMedicalServicesEmergencyMedicalServices:methodsEndovascularProceduresEndovascularProcedures:mortalityFemaleHumanizedHumanized:administration&dosageHumansIntensity-ModulatedIntensity-Modulated:adverseeffectsKidneyNeoplasmsKidneyNeoplasms:mortalityKidneyNeoplasms:surgeryLungNeoplasmsLungNeoplasms:drugtherapyMaleMedicareMedicare:statistics&numericaldataMonoclonalNephrectomyNephrectomy:methodsNephrectomy:mortalityNon-Small-CellLungNon-Small-CellLung:drugtherapyProstaticNeoplasmsProstaticNeoplasms:radiotherapyRadiationInjuriesRadiotherapyVascularSurgicalProceduresVascularSurgicalProcedures:mortalityWoundsandInjuriesWoundsandInjuries:mortality
(0)
copydeleteadd this publication to your clipboard
1Statistical methods for the analysis of relapse data in MS clinical trials.
Y. Wang, L. Meyerson, Y. Tang, and N. Qian. Journal of the neurological sciences, 285 (1-2): 206-11 (October 2009)5489<m:linebreak></m:linebreak>JID: 0375403; 0 (Antibodies, Monoclonal); 0 (Immunologic Factors); 0 (natalizumab); 2009/03/05 received; 2009/07/15 revised; 2009/07/22 accepted; 2009/08/25 aheadofprint; ppublish;<m:linebreak></m:linebreak>Anàlisi de dades; Count data.
2 years ago by @jepcastel
show all tags
Adult
Antibodies
BinomialDistribution
BiomedicalResearch
BiomedicalResearch:methods
ClinicalTrialsasTopic
Computers
Female
Humanized
Humans
ImmunologicFactors
ImmunologicFactors:therapeuticuse
Male
Models
Monoclonal
Monoclonal:therapeuticuse
MultipleSclerosis
MultipleSclerosis:drugtherapy
MultipleSclerosis:therapy
PoissonDistribution
ProportionalHazardsModels
Recurrence
RegressionAnalysis
Software
Statistical
TimeFactors
TreatmentOutcome
AdultAntibodiesBinomialDistributionBiomedicalResearchBiomedicalResearch:methodsClinicalTrialsasTopicComputersFemaleHumanizedHumansImmunologicFactorsImmunologicFactors:therapeuticuseMaleModelsMonoclonalMonoclonal:therapeuticuseMultipleSclerosisMultipleSclerosis:drugtherapyMultipleSclerosis:therapyPoissonDistributionProportionalHazardsModelsRecurrenceRegressionAnalysisSoftwareStatisticalTimeFactorsTreatmentOutcome
(0)
copydeleteadd this publication to your clipboard
1Poor reporting of search strategy and conflict of interest in over 250 narrative and systematic reviews of two biologic agents in arthritis: a systematic review.
A. Roundtree, M. Kallen, M. Lopez-Olivo, B. Kimmel, B. Skidmore, Z. Ortiz, V. Cox, and M. Suarez-Almazor. Journal of clinical epidemiology, 62 (2): 128-37 (February 2009)5016<m:linebreak></m:linebreak>GR: 5 K24 AR053593/AR/NIAMS NIH HHS/United States; GR: 5 U18 HS016093/HS/AHRQ HHS/United States; JID: 8801383; 2008/01/04 received; 2008/08/15 revised; 2008/08/18 accepted; 2008/11/14 aheadofprint; ppublish;<m:linebreak></m:linebreak>Metaanàlisi.
2 years ago by @jepcastel
show all tags
Antibodies
AntirheumaticAgents
AntirheumaticAgents:therapeuticuse
Arthritis
ConflictofInterest
Humans
ImmunoglobulinG
ImmunoglobulinG:therapeuticuse
JournalImpactFactor
Meta-AnalysisasTopic
Monoclonal
Monoclonal:therapeuticuse
PeerReview
Publishing
Publishing:standards
Receptors
ReviewLiteratureasTopic
Rheumatoid
Rheumatoid:drugtherapy
TumorNecrosisFactor
TumorNecrosisFactor:therapeuticuse
AntibodiesAntirheumaticAgentsAntirheumaticAgents:therapeuticuseArthritisConflictofInterestHumansImmunoglobulinGImmunoglobulinG:therapeuticuseJournalImpactFactorMeta-AnalysisasTopicMonoclonalMonoclonal:therapeuticusePeerReviewPublishingPublishing:standardsReceptorsReviewLiteratureasTopicRheumatoidRheumatoid:drugtherapyTumorNecrosisFactorTumorNecrosisFactor:therapeuticuse
(0)
copydeleteadd this publication to your clipboard
1Immortal time bias in estimates of mortality among infliximab-treated patients with Crohn's disease.
J. Lewis. Gut, 59 (11): 1586-7 (November 2010)5816<m:linebreak></m:linebreak>JID: 2985108R; 0 (Antibodies, Monoclonal); 0 (Gastrointestinal Agents); 0 (infliximab); CON: Gut. 2009 Apr;58(4):501-8. PMID: 18832524; 2010/08/23 aheadofprint; ppublish;.
2 years ago by @jepcastel
show all tags
Antibodies
Bias(Epidemiology)
CrohnDisease
CrohnDisease:drugtherapy
DataInterpretation
GastrointestinalAgents
GastrointestinalAgents:adverseeffects
Humans
Monoclonal
Monoclonal:adverseeffects
ResearchDesign
Statistical
AntibodiesBias(Epidemiology)CrohnDiseaseCrohnDisease:drugtherapyDataInterpretationGastrointestinalAgentsGastrointestinalAgents:adverseeffectsHumansMonoclonalMonoclonal:adverseeffectsResearchDesignStatistical
(0)
copydeleteadd this publication to your clipboard
1Ophthalmic statistics note 2: absence of evidence is not evidence of absence.
C. Bunce, K. Patel, W. Xing, N. Freemantle, and C. Doré. The British journal of ophthalmology, 98 (5): 703-5 (May 2014)Tests d'equivalència; Límits de confiança; Oftalmologia; Introductori.
2 years ago by @jepcastel
show all tags
AngiogenesisInhibitors
AngiogenesisInhibitors:administration&dosage
AngiogenesisInhibitors:adverseeffects
Antibodies
Evidence-BasedMedicine
Evidence-BasedMedicine:education
Gravitation
Humanized
Humanized:administration
Humanized:adverseeffects
Humans
MacularDegeneration
MacularDegeneration:drugtherapy
MacularDegeneration:rehabilitation
MacularDegeneration:surgery
Monoclonal
Ophthalmology
Ophthalmology:education
PostoperativeComplications
PostoperativeComplications:epidemiology
PostoperativeComplications:etiology
PostoperativeComplications:prevention&control
Posture
Reoperation
Reoperation:statistics&numericaldata
RetinalPerforations
RetinalPerforations:drugtherapy
RetinalPerforations:rehabilitation
RetinalPerforations:surgery
RiskAssessment
RiskFactors
Vitrectomy
Vitrectomy:adverseeffects
Vitrectomy:rehabilitation
AngiogenesisInhibitorsAngiogenesisInhibitors:administration&dosageAngiogenesisInhibitors:adverseeffectsAntibodiesEvidence-BasedMedicineEvidence-BasedMedicine:educationGravitationHumanizedHumanized:administrationHumanized:adverseeffectsHumansMacularDegenerationMacularDegeneration:drugtherapyMacularDegeneration:rehabilitationMacularDegeneration:surgeryMonoclonalOphthalmologyOphthalmology:educationPostoperativeComplicationsPostoperativeComplications:epidemiologyPostoperativeComplications:etiologyPostoperativeComplications:prevention&controlPostureReoperationReoperation:statistics&numericaldataRetinalPerforationsRetinalPerforations:drugtherapyRetinalPerforations:rehabilitationRetinalPerforations:surgeryRiskAssessmentRiskFactorsVitrectomyVitrectomy:adverseeffectsVitrectomy:rehabilitation
(0)
copydeleteadd this publication to your clipboard
1Ophthalmic Statistics Note 4: analysing data from randomised controlled trials with baseline and follow-up measurements.
R. Nash, C. Bunce, N. Freemantle, C. Doré, and C. Rogers. The British journal of ophthalmology, 98 (11): 1467-9 (November 2014)Anàlisi de dades; Canvi.
2 years ago by @jepcastel
show all tags
AngiogenesisInhibitors
AngiogenesisInhibitors:therapeuticuse
Antibodies
DataInterpretation
Follow-UpStudies
Humanized
Humanized:therapeuticuse
Humans
MacularDegeneration
MacularDegeneration:drugtherapy
MacularDegeneration:physiopathology
Monoclonal
Statistical
VascularEndothelialGrowthFactorA
VascularEndothelialGrowthFactorA:antagonists
VisualAcuity
VisualAcuity:drugeffects
VisualAcuity:physiology
RCT
AngiogenesisInhibitorsAngiogenesisInhibitors:therapeuticuseAntibodiesDataInterpretationFollow-UpStudiesHumanizedHumanized:therapeuticuseHumansMacularDegenerationMacularDegeneration:drugtherapyMacularDegeneration:physiopathologyMonoclonalStatisticalVascularEndothelialGrowthFactorAVascularEndothelialGrowthFactorA:antagonistsVisualAcuityVisualAcuity:drugeffectsVisualAcuity:physiologyRCT
(0)
copydeleteadd this publication to your clipboard
2Surrogate predictive biomarkers for response to anti-EGFR agents: state of the art and challenges
F. Cappuzzo, L. Toschi, G. Finocchiaro, C. Ligorio, and A. Santoro. Int.J.Biol.Markers, 22 (1 Suppl 4): S10-S23 (2007)
15 years ago by @jabreftest
show all tags
inhibitors
Monoclonal
Tyrosine
antagonists
c-akt
Predictive
of
Phosphoproteins
Protein-Tyrosine
Resistance
protein
Drug
Protein
Epidermal
Value
&
Factor
identify
erbB-3
erbB-2
effects
Carcinoma
Neoplasms
Non-Small-Cell
Tests
Biological
therapy
Mutation
therapeutic
Human
Humans
use
analysis
Kinases
response
Growth
Neoplasm
Inhibitors
Markers
Kinase
drug
Gene
Quinazolines
Receptor
genetics
Antibodies
Lung
Dosage
Proto-Oncogene
Proteins
Immunohistochemistry
inhibitorsMonoclonalTyrosineantagonistsc-aktPredictiveofPhosphoproteinsProtein-TyrosineResistanceproteinDrugProteinEpidermalValue&FactoridentifyerbB-3erbB-2effectsCarcinomaNeoplasmsNon-Small-CellTestsBiologicaltherapyMutationtherapeuticHumanHumansuseanalysisKinasesresponseGrowthNeoplasmInhibitorsMarkersKinasedrugGeneQuinazolinesReceptorgeneticsAntibodiesLungDosageProto-OncogeneProteinsImmunohistochemistry
(0)
copydeleteadd this publication to your clipboard
1Key elements of bioanalytical method validation for macromolecules
M. Kelley, and B. DeSilva. AAPS.J., 9 (2): E156-E163 (2007)
15 years ago by @kanefendt
show all tags
Antibodies
Binding
Chemistry
Immunoassay
Indicators
Ligands
Macromolecular
Monoclonal
Pharmaceutical
Pharmacokinetics
Preparations
Reagents
Reference
Reproducibility
Results
Sensitivity
Specificity
Standards
Substances
analysis
and
metabolism
methods
of
standards
AntibodiesBindingChemistryImmunoassayIndicatorsLigandsMacromolecularMonoclonalPharmaceuticalPharmacokineticsPreparationsReagentsReferenceReproducibilityResultsSensitivitySpecificityStandardsSubstancesanalysisandmetabolismmethodsofstandards
(0)
copydeleteadd this publication to your clipboard
1Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth
P. Laakkonen, M. Waltari, T. Holopainen, T. Takahashi, B. Pytowski, P. Steiner, D. Hicklin, K. Persaud, J. Tonra, L. Witte and 1 other author(s). Cancer Res., 67 (2): 593-599 (2007)
15 years ago by @kanefendt
show all tags
&
Animals
Antibodies
Antitumor
Assays
BALB
Binding
C
Cell
D
Endothelial
Factor
Growth
Human
Humans
Immunohistochemistry
Inbred
Ligands
Mice
Model
Monoclonal
Neoplasms
Neovascularization
Nude
Pathologic
Processes
Receptor-3
Research
Vascular
Xenograft
analysis
antagonists
blood
immunology
inhibitors
metabolism
pharmacology
supply
therapy
&AnimalsAntibodiesAntitumorAssaysBALBBindingCCellDEndothelialFactorGrowthHumanHumansImmunohistochemistryInbredLigandsMiceModelMonoclonalNeoplasmsNeovascularizationNudePathologicProcessesReceptor-3ResearchVascularXenograftanalysisantagonistsbloodimmunologyinhibitorsmetabolismpharmacologysupplytherapy
(0)
copydeleteadd this publication to your clipboard
1The biology of epidermal growth factor receptor and its value as a prognostic/predictive factor
A. Tos. Int.J.Biol.Markers, 22 (1 Suppl 4): S3-S9 (2007)
15 years ago by @kanefendt
show all tags
Antibodies
Biological
Epidermal
Expression
Factor
Gene
Growth
Human
Humans
Immunohistochemistry
Markers
Monoclonal
Neoplasms
Neoplastic
Prognosis
Receptor
Regulation
Tyrosine
analysis
drug
effects
etiology
identify
pathology
physiology
response
therapeutic
therapy
use
AntibodiesBiologicalEpidermalExpressionFactorGeneGrowthHumanHumansImmunohistochemistryMarkersMonoclonalNeoplasmsNeoplasticPrognosisReceptorRegulationTyrosineanalysisdrugeffectsetiologyidentifypathologyphysiologyresponsetherapeutictherapyuse
(0)
copydeleteadd this publication to your clipboard
2Surrogate predictive biomarkers for response to anti-EGFR agents: state of the art and challenges
F. Cappuzzo, L. Toschi, G. Finocchiaro, C. Ligorio, and A. Santoro. Int.J.Biol.Markers, 22 (1 Suppl 4): S10-S23 (2007)
15 years ago by @kanefendt
show all tags
&
Antibodies
Biological
Carcinoma
Dosage
Drug
Epidermal
Factor
Gene
Growth
Human
Humans
Immunohistochemistry
Inhibitors
Kinase
Kinases
Lung
Markers
Monoclonal
Mutation
Neoplasm
Neoplasms
Non-Small-Cell
Phosphoproteins
Predictive
Protein
Protein-Tyrosine
Proteins
Proto-Oncogene
Quinazolines
Receptor
Resistance
Tests
Tyrosine
Value
analysis
antagonists
c-akt
drug
effects
erbB-2
erbB-3
genetics
identify
inhibitors
of
protein
response
therapeutic
therapy
use
&AntibodiesBiologicalCarcinomaDosageDrugEpidermalFactorGeneGrowthHumanHumansImmunohistochemistryInhibitorsKinaseKinasesLungMarkersMonoclonalMutationNeoplasmNeoplasmsNon-Small-CellPhosphoproteinsPredictiveProteinProtein-TyrosineProteinsProto-OncogeneQuinazolinesReceptorResistanceTestsTyrosineValueanalysisantagonistsc-aktdrugeffectserbB-2erbB-3geneticsidentifyinhibitorsofproteinresponsetherapeutictherapyuse
(0)
copydeleteadd this publication to your clipboard
1Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition
T. Force, D. Krause, and R. van Etten. Nat.Rev.Cancer, 7 (5): 332-344 (2007)
15 years ago by @kanefendt
show all tags
&
Adaptor
Antibodies
Benzenesulfonates
Biological
Delivery
Diseases
Drug
Enzyme
Heart
Human
Humans
Indoles
Inhibitors
Kinase
Kinases
Models
Monoclonal
Mutation
Neoplasms
Protein
Protein-Tyrosine
Proteins
Proto-Oncogene
Pyridines
Pyrroles
Quinazolines
Research
Signal
Systems
Transducing
Tyrosine
adverse
antagonists
c-abl
cells
chemically
development
drug
effects
growth
induced
inhibitors
physiology
protein
response
therapy
toxicity
&AdaptorAntibodiesBenzenesulfonatesBiologicalDeliveryDiseasesDrugEnzymeHeartHumanHumansIndolesInhibitorsKinaseKinasesModelsMonoclonalMutationNeoplasmsProteinProtein-TyrosineProteinsProto-OncogenePyridinesPyrrolesQuinazolinesResearchSignalSystemsTransducingTyrosineadverseantagonistsc-ablcellschemicallydevelopmentdrugeffectsgrowthinducedinhibitorsphysiologyproteinresponsetherapytoxicity
(0)
copydeleteadd this publication to your clipboard
1The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review
F. Eskens, and J. Verweij. Eur.J.Cancer, 42 (18): 3127-3139 (2006)
15 years ago by @kanefendt
show all tags
&
A
Angiogenesis
Antibodies
Endothelial
Factor
Growth
Humans
Inhibitors
Kinase
Kinases
Medical
Monoclonal
Neoplasms
Neovascularization
Oncology
Pathologic
Protein
Protein-Tyrosine
Receptors
Tyrosine
Vascular
adverse
antagonists
blood
control
drug
effects
inhibitors
prevention
protein
supply
therapy
toxicity
&AAngiogenesisAntibodiesEndothelialFactorGrowthHumansInhibitorsKinaseKinasesMedicalMonoclonalNeoplasmsNeovascularizationOncologyPathologicProteinProtein-TyrosineReceptorsTyrosineVascularadverseantagonistsbloodcontroldrugeffectsinhibitorspreventionproteinsupplytherapytoxicity
(0)
copydeleteadd this publication to your clipboard
1Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan
B. Vincenzi, D. Santini, A. Russo, M. Gavasci, F. Battistoni, G. Dicuonzo, L. Rocci, V. Rosaria, N. Gebbia, and G. Tonini. Pharmacogenomics., 8 (4): 319-327 (2007)
15 years ago by @kanefendt
show all tags
&
A
Adult
Aged
Antibodies
Antineoplastic
Biological
Camptothecin
Chemotherapy
Colorectal
Combined
Disease
Endothelial
Factor
Female
Growth
Humans
Male
Markers
Medical
Middle
Monoclonal
Neoplasms
Oncology
Outcome
Progression
Prospective
Protocols
Rate
Studies
Survival
Treatment
Tumor
Vascular
administration
analogs
antagonists
blood
derivatives
dosage
drug
inhibitors
methods
mortality
response
therapeutic
therapy
trends
use
&AAdultAgedAntibodiesAntineoplasticBiologicalCamptothecinChemotherapyColorectalCombinedDiseaseEndothelialFactorFemaleGrowthHumansMaleMarkersMedicalMiddleMonoclonalNeoplasmsOncologyOutcomeProgressionProspectiveProtocolsRateStudiesSurvivalTreatmentTumorVascularadministrationanalogsantagonistsbloodderivativesdosagedruginhibitorsmethodsmortalityresponsetherapeutictherapytrendsuse
(0)
copydeleteadd this publication to your clipboard
1Critical ligand binding reagent preparation/selection: when specificity depends on reagents
B. Rup, and D. O'Hara. AAPS.J., 9 (2): E148-E155 (2007)
15 years ago by @kanefendt
show all tags
Antibodies
Binding
Chemistry
Immunoassay
Indicators
Ligands
Monoclonal
Pharmaceutical
Pharmacokinetics
Preparations
Reagents
Reproducibility
Research
Results
Safety
Sensitivity
Specificity
and
metabolism
methods
of
standards
AntibodiesBindingChemistryImmunoassayIndicatorsLigandsMonoclonalPharmaceuticalPharmacokineticsPreparationsReagentsReproducibilityResearchResultsSafetySensitivitySpecificityandmetabolismmethodsofstandards
(0)
copydeleteadd this publication to your clipboard
1Monoclonal antibodies against epidermal growth factor receptor in advanced colorectal carcinoma: clinical efficacy and markers of sensitivity
E. Carcereny, and J. Maurel. Rev.Recent Clin.Trials, 1 (2): 113-118 (2006)
15 years ago by @kanefendt
show all tags
&
Animals
Antibodies
Biomarkers
Carcinoma
Colorectal
Drug
Epidermal
Europe
Factor
Factors
Growth
Humans
Immunologic
Ligands
Medical
Monoclonal
Mutation
Neoplasm
Neoplasms
Oncology
Pharmacological
Phosphorylation
Prognosis
Receptor
Resistance
Tyrosine
antagonists
genetics
inhibitors
pharmacology
response
therapeutic
therapy
use
&AnimalsAntibodiesBiomarkersCarcinomaColorectalDrugEpidermalEuropeFactorFactorsGrowthHumansImmunologicLigandsMedicalMonoclonalMutationNeoplasmNeoplasmsOncologyPharmacologicalPhosphorylationPrognosisReceptorResistanceTyrosineantagonistsgeneticsinhibitorspharmacologyresponsetherapeutictherapyuse
(0)
copydeleteadd this publication to your clipboard
1How well do angiogenesis inhibitors work? Biomarkers of response prove elusive
V. Brower. J.Natl.Cancer Inst., 101 (12): 846-847 (2009)
15 years ago by @kanefendt
show all tags
A
Analysis
Angiogenesis
Animals
Antibodies
Benzenesulfonates
Biological
Cells
Cytokines
Disease-Free
Endothelial
Factor
Growth
Humans
Indoles
Inhibitors
Markers
Monoclonal
Neoplasms
Pyridines
Pyrroles
Survival
Tumor
Vascular
blood
drug
effects
metabolism
mortality
pathology
pharmacology
response
supply
therapeutic
therapy
use
AAnalysisAngiogenesisAnimalsAntibodiesBenzenesulfonatesBiologicalCellsCytokinesDisease-FreeEndothelialFactorGrowthHumansIndolesInhibitorsMarkersMonoclonalNeoplasmsPyridinesPyrrolesSurvivalTumorVascularblooddrugeffectsmetabolismmortalitypathologypharmacologyresponsesupplytherapeutictherapyuse
(0)
copydeleteadd this publication to your clipboard
1Antiangiogenesis research is booming, as questions and studies proliferate
V. Brower. J.Natl.Cancer Inst., 101 (11): 780-781 (2009)
15 years ago by @kanefendt
show all tags
&
Administration
Analysis
Angiogenesis
Antibodies
Antineoplastic
Biological
Chemotherapy
Colorectal
Combined
Controlled
Drug
Humans
Inhibitors
Markers
Monoclonal
Neoplasms
Pericytes
Protocols
Randomized
Research
Schedule
Survival
Topic
Trials
Tumor
administration
analysis
as
blood
dosage
drug
effects
mortality
supply
therapeutic
therapy
use
&AdministrationAnalysisAngiogenesisAntibodiesAntineoplasticBiologicalChemotherapyColorectalCombinedControlledDrugHumansInhibitorsMarkersMonoclonalNeoplasmsPericytesProtocolsRandomizedResearchScheduleSurvivalTopicTrialsTumoradministrationanalysisasblooddosagedrugeffectsmortalitysupplytherapeutictherapyuse
(0)
copydeleteadd this publication to your clipboard
2Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100
B. Schneider, M. Wang, M. Radovich, G. Sledge, S. Badve, A. Thor, D. Flockhart, B. Hancock, N. Davidson, J. Gralow and 6 other author(s). J.Clin.Oncol., 26 (28): 4672-4678 (2008)
15 years ago by @kanefendt
show all tags
&
A
Antibodies
Antineoplastic
Breast
Chemotherapy
Combined
Dna
Endothelial
Factor
Female
Genotype
Growth
Haplotypes
Hazards
Humans
Hypertension
Models
Monoclonal
Neoplasms
Nonparametric
Nucleotide
Paclitaxel
Polymorphism
Proportional
Protocols
Rate
Receptor-2
Research
Retrospective
Single
Statistics
Studies
Survival
Vascular
administration
dosage
drug
genetics
methods
pathology
therapeutic
therapy
toxicity
use
&AAntibodiesAntineoplasticBreastChemotherapyCombinedDnaEndothelialFactorFemaleGenotypeGrowthHaplotypesHazardsHumansHypertensionModelsMonoclonalNeoplasmsNonparametricNucleotidePaclitaxelPolymorphismProportionalProtocolsRateReceptor-2ResearchRetrospectiveSingleStatisticsStudiesSurvivalVascularadministrationdosagedruggeneticsmethodspathologytherapeutictherapytoxicityuse
(0)
copydeleteadd this publication to your clipboard

⟨⟨
⟨
1
2
⟩
⟩⟩

BibSonomy

bookmarks (hide)
display
all
bookmarks only
bookmarks per page
5
10
20
50
100
sort by
added at
title
RSS
BibTeX
XML

publications (hide)35
display
all
publications only
publications per page
5
10
20
50
100
sort by
added at
title
author
publication date
entry type
help for advanced sorting...
RSS
BibTeX
RDF
more...

1The Immunotherapy in Cancer Treatment Occurring Advancement in Using the Immune System to Combat Cancer

1Is it time for medicine-based evidence?

1Statistical methods for the analysis of relapse data in MS clinical trials.

1Poor reporting of search strategy and conflict of interest in over 250 narrative and systematic reviews of two biologic agents in arthritis: a systematic review.

1Immortal time bias in estimates of mortality among infliximab-treated patients with Crohn's disease.

1Ophthalmic statistics note 2: absence of evidence is not evidence of absence.

1Ophthalmic Statistics Note 4: analysing data from randomised controlled trials with baseline and follow-up measurements.

2Surrogate predictive biomarkers for response to anti-EGFR agents: state of the art and challenges

1Key elements of bioanalytical method validation for macromolecules

1Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth

1The biology of epidermal growth factor receptor and its value as a prognostic/predictive factor

2Surrogate predictive biomarkers for response to anti-EGFR agents: state of the art and challenges

1Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition

1The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review

1Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan

1Critical ligand binding reagent preparation/selection: when specificity depends on reagents

1Monoclonal antibodies against epidermal growth factor receptor in advanced colorectal carcinoma: clinical efficacy and markers of sensitivity

1How well do angiogenesis inhibitors work? Biomarkers of response prove elusive

1Antiangiogenesis research is booming, as questions and studies proliferate

2Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100

browse

related tags

bookmarks (hide) displayallbookmarks onlybookmarks per page5102050100 sort byadded attitle RSSBibTeXXML

publications (hide)35 displayallpublications onlypublications per page5102050100 sort byadded attitleauthorpublication dateentry typehelp for advanced sorting... RSSBibTeXRDFmore...

browse

related tags

bookmarks (hide)
display
all
bookmarks only
bookmarks per page
5
10
20
50
100
sort by
added at
title
RSS
BibTeX
XML

publications (hide)35
display
all
publications only
publications per page
5
10
20
50
100
sort by
added at
title
author
publication date
entry type
help for advanced sorting...
RSS
BibTeX
RDF
more...